Selected Publications

1. Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.  Benton A, Liu J, Poussin MA, Lang Goldgewicht A, Udawela M, Bear AS, Wellhausen N, Carreno BM, Smith PM, Beasley MD, Kiefel BR, Powell DJ Jr. Cancer Cell. 2025 Jul 14;43(7):1365-1376.e5. doi: 10.1016/j.ccell.2025.05.006. Epub 2025 Jun 5. PMID: 40480232
2. CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival. Tubridy EA, Eiva MA, Liu F, Omran DK, Gysler S, Brown EG, Roy AG, Zeng Y, Oh J, Cao Q, Gitto SB, Powell DJ Jr. Gynecol Oncol. 2024 May;184:74-82. doi: 10.1016/j.ygyno.2024.01.029. Epub 2024 Jan 29. PMID: 38290413
3. A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, Pétremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroyannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, Stevenson BJ, Iseli C, Levine BL, Speiser DE, Gfeller D, Bassani-Sternberg M, Powell DJ Jr, June CH, Dafni U, Kandalaft LE, Harari A, Coukos G. Nat Cancer. 2023 Oct;4(10):1410-1417. doi: 10.1038/s43018-023-00623-x. Epub 2023 Sep 21. PMID: 37735588
4. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.  Smole A, Benton A, Poussin MA, Eiva MA, Mezzanotte C, Camisa B, Greco B, Sharma P, Minutolo NG, Gray F, Bear AS, Baroja ML, Cummins C, Xu C, Sanvito F, Goldgewicht AL, Blanchard T, Rodriguez-Garcia A, Klichinsky M, Bonini C, June CH, Posey AD Jr, Linette GP, Carreno BM, Casucci M, Powell DJ Jr. Cancer Cell. 2022 Dec 12;40(12):1470-1487.e7. doi: 10.1016/j.ccell.2022.11.006. PMID: 36513049
5. Generation of functional canine TIL products for solid tumors.  Foos KM, Pandey V, Jennings MW, Powell DJ Jr, Mason NJ. Front Immunol. 2026 May 13;17:1810955. doi: 10.3389/fimmu.2026.1810955. eCollection 2026. PMID: 42212155

NCBI bibliography: https://www.ncbi.nlm.nih.gov/myncbi/daniel.powell.2/bibliography/public/